Pfizer Confirms Paxlovid’s High Efficacy And Reassures On Omicron
89% Relative Risk Reduction Confirmed
While Merck & Co’s Lagevrio’s results declined after an interim readout, Pfizer’s oral COVID-19 candidate Paxlovid has maintained its strong performance in protecting high-risk patients from hospitalization or death.
You may also be interested in...
The company announced updated results from a standard-risk study, which it will include in its overall new drug application, but whether Paxlovid will see approval or uptake in that group is another question.
Simcere is weighing options for SIM0417 in a Phase I trial in China as the first major domestically-developed potential rival to Pfizer’s oral COVID-19 antiviral Paxlovid. The study is likely to include wider patient groups ranging from those without symptoms to severe patients.
Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.